The Pharma Data

AUGUST 22, 2021

a CheckMate -274 primary investigator and Professor of Medicine, Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer, and Associate Director for Translational Research at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai. Galsky,* M.D.,

Drugs 52

Drugs HR FDA Approval Trials 52

XTalks

DECEMBER 20, 2023

Novo Nordisk’s GLP-1 weight loss-specific drug Wegovy (semaglutide) has been facing similar shortages, as it contains the same active ingredient as Ozempic. The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 52

Production Dermatology Development Containment 52

The Pharma Data

NOVEMBER 4, 2020

Both of our clinical candidates represent important opportunities for new medicines that we hope will have a meaningful impact on the lives of patients.”. Published Findings on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology. Research and development expenses were $16.3 R&D Expenses.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Dermatology 52

Bioengineer

JULY 20, 2021

Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Octagam® 10% does not contain sucrose. ” Dermatomyositis is a rare idiopathic autoimmune disorder of unknown cause affecting approximately 10 out of every million U.S.

FDA Approval 40

FDA Approval Clinical Trials Clinical Trials Trials 40

The Pharma Data

APRIL 28, 2021

These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14. IR main line: Tel.: +33

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 40

Production Dermatology Development Containment 40

The Pharma Data

MAY 18, 2021

This included net special gains of 15 million euros (Q1 2020: net special charges of 639 million euros), with income from a patent dispute related to the blood-clotting medicine Jivi™ more than offsetting the expenses for the ongoing restructuring program. EBIT increased by 23.4 percent to 3.083 billion euros. Net income rose by 40.3

Sales 40

Sales Production Marketing Containment 40

The Pharma Data

JANUARY 26, 2021

BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Reddy’s Laboratories Ltd.

Life Science 40

Life Science Production Marketing Dermatology 40

The Pharma Data

JULY 11, 2021

Hereditary angioedema is a lifelong condition and research shows that concerns about another attack can limit the way patients lead their lives,” said Prof. Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin in Berlin, Germany. percent (-100; 852.8), and the median reduction was 97.7 Contraindication.

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

The Pharma Data

OCTOBER 26, 2020

The European Medicines Agency (EMA) has also accepted the Marketing Authorization Application (MAA) for abrocitinib in the same patient population with a decision anticipated in the second half of 2021. The FDA is expected to make a decision in April 2021.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Medicine 40

The Pharma Data

MARCH 3, 2021

Symbicort (budesonide/formoterol) is a combination formulation containing budesonide, an inhaled corticosteroid that treats underlying inflammation, and formoterol, a long-acting beta2-agonist bronchodilator with a fast onset of action, in a single inhaler. Source link:[link].

Dermatology 52

Dermatology Drug Delivery Medicine Containment 52

The Pharma Data

NOVEMBER 12, 2020

Information from the World Health Organization indicates that over the past 10 years, reports of suicidal ideation among young men using the drug have increased, rising significantly after 2012, the researchers said. 11 in JAMA Dermatology. Its use was later extended to treat male-pattern baldness. The report was published online Nov.

Dermatology 52

Dermatology Drugs Packaging Packaging 52

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

APRIL 26, 2021

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. Excluding prior year COVID-19 related forward purchasing , we estimate Q1 net sales grew +1% (cc, +4% USD), with Innovative Medicines growing +3% (cc, +7% USD)².

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

APRIL 4, 2023

Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who are not eligible for cisplatin-containing chemotherapy.

FDA Approval 40

FDA Approval Containment Hormones Dermatology 40

The Pharma Data

SEPTEMBER 15, 2020

I am proud of the truly transformational science that our research and clinical teams are bringing to the fight against disease, as well as the unprecedented speed with which we are advancing our clinical programs in the battle against COVID-19. Internal Medicine. THERAPEUTIC AREAS OF FOCUS. Inflammation and Immunology.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

JULY 23, 2021

The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. endocrinopathies and dermatologic reactions) are discussed below. Immune-Mediated Dermatologic Adverse Reactions OPDIVO can cause immune-mediated rash or dermatitis.

Hormones 52

Hormones Trials Genome Genomics 52

Pfizer

OCTOBER 28, 2022

NYSE: PFE) announced today that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded their assessment of Janus kinase (JAK) inhibitors authorized for the treatment of certain inflammatory diseases in the European Union (EU) and has provided updated recommendations for their use.

Clinical Trials 40

Clinical Trials Clinical Trials Vaccination Vaccine 40

The Pharma Data

MARCH 11, 2021

The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. endocrinopathies and dermatologic reactions) are discussed below. Immune-Mediated Dermatologic Adverse Reactions. Immune-Mediated Pneumonitis.

Trials 52

Trials Hormones Genome Genomics 52

The Pharma Data

AUGUST 11, 2020

Bristol Myers Squibb: Advancing Cancer Research. The goal of our cancer research is to increase patients’ quality of life, long-term survival and make cure a possibility. Immune-Mediated Skin and Dermatologic Adverse Reactions. While GEJ cancer has a lower prevalence than gastric cancer, it continues to rise. About Opdivo.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

Bristol Myers Squibb: Advancing Cancer Research. The goal of our cancer research is to increase patients’ quality of life, long-term survival and make cure a possibility. Immune-Mediated Skin and Dermatologic Adverse Reactions. At Bristol Myers Squibb, patients are at the center of everything we do. About Opdivo.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

Delveinsight

AUGUST 13, 2020

It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, a long-acting beta2-adrenergic agonist, delivered in GSK’s Ellipta dry powder inhaler. Preclinical research showed SAR440340 blocked several markers of both types of inflammation.

Antibody 40

Antibody Medicine Trials Development 40